Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.63 |
| ▸ | FDPS | P14324 | 2/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762419 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7979864 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27581948 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL29785749 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1039370 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4028421 | 0.83 | GRIN2D (0.61) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL12532007 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7085644 | 0.83 | PTPRA (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18622385 | 0.81 | GRIN2D (0.59) | PTPRAFDPSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1856670 | 0.80 | HRH1 (0.57) | PTPRAFDPSHRH1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117368160-A | Method for verifying iron death in neurodegenerative diseases and application of method | 西南医科大学 | 2024-01-09 | — | — | CN | claimed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | claimed |
| EP-0435127-A2 | 3-Substituted pyridines | BASF Aktiengesellschaft (DE) | 1991-07-03 | — | — | EP | claimed |
| CN-117368160-A | Method for verifying iron death in neurodegenerative diseases and application of method | 西南医科大学 | 2024-01-09 | — | — | CN | disclosed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| EP-1153919-A4 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORP (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000048997-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE β3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2000-08-24 | — | — | WO | disclosed |
| US-5194441-A | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
| US-4138410-A | Flavoring agent | FIRMENICH & CIE (CH) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | PTPRA 4519/4885FDPS 1838/4885GRIN2D 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.